Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118313 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00118313: Completed Phase 1 study, sponsored by Craig L Slingluff, Jr.
NCT00118313 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118313, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL multi-epitope melanoma peptide vaccine
- BIOLOGICAL tetanus toxoid helper peptide
- DRUG dimethyl sulfoxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11-04 |
| Est. Completion | 2006-07-28 |
| Phase | Phase 1 |
What the finished NCT00118313 record still lists
NCT00118313 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which sargramostim is the first listed.
NCT00118313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00118313 about?
NCT00118313 is a clinical study titled "Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery ...
What is the current status of trial NCT00118313?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-11-04. Estimated completion is 2006-07-28.
What interventions are being tested in trial NCT00118313?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL), tetanus toxoid helper peptide (BIOLOGICAL), dimethyl sulfoxide (DRUG).
Who is sponsoring clinical trial NCT00118313?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI